Fig 2: YTHDF2 is highly upregulated in patients with bladder carcinoma. A, Association of YTHDF2 expression and mutations in TCGA bladder carcinoma. B, Relative YTHDF2 expression level in NMIBC and MIBC from the GEO dataset GSE77952 (left) and in recurrence samples compared with primary tumors from GEO dataset GSE128959 (right). C, The fluorescence intensity of YTHDF2, EpCAM (epithelial marker), and DAPI by multiplex immunofluorescence (MIHC) staining assays. D, Representative images of TMA-based IHC staining of YTHDF2 in bladder carcinoma samples. E, The IHC expression differences between MIBC and NMIBC. Statistical analysis was performed with the nonparametric Mann–Whitney test. F, The overall survival using TMA-based IHC staining of YTHDF2 in bladder carcinoma samples. P values in A were calculated using the ?2 test. P values in D and E were calculated with the nonparametric Mann–Whitney test. Survival rate (F) was compared by log-rank (Mantel–Cox) test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.